Rhubarb for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
Rhubarb may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed rhubarb in detail.
, Analysis of molecular mechanism of Chinese medicine Jinhong decoction (JHD) in synergistically treating sepsis and COVID-19 based on network pharmacology, PLOS One, doi:10.1371/journal.pone.0339457
Sepsis and COVID-19 are the two mutually-reinforcing risk factors, whose interaction drastically increases mortality rate. Jinhong decoction (JHD) as a Chinese medicine exhibits clinical efficacy against them, but related action mechanism remains to be explored. To this end, using network pharmacology, this study screened active ingredients of JHD and their targets from TCMSP, HERB, PubChem and SwissTargetPrediction databases as well as the targets for these two diseases from DisGeNET, OMIM, Drugbank, TTD, and GeneCards. By intersecting drug and disease targets, we identified common targets and constructed a drug-ingredient-target network. GO and KEGG enrichment analyses revealed key target-related signaling pathways, and transcriptomics analysis further validated tissue distribution of these targets and their expressions. Our identified six key target genes ( AKT1 , MMP9 , ICAM1 , TLR4 , BCL2 , and HIF1A ) were mainly involved in the regulations of immunometabolism, inflammation, and cell survival in both diseases. Functional enrichment analysis indicated that JHD displayed synergistic efficacy against both diseases by simultaneously modulating HIF-1, TNF, and NF-κB signaling pathways. Tissue distribution analyses of these 6 key target genes revealed that CD33 + myeloid cells, fetal lung cells, and bronchial epithelial cells might play an important role in treating both diseases. Overall, this study demonstrates that JHD treats sepsis and COVID-19 through a multi-ingredient, multi-target, and multi-pathway inter-related mechanism, exhibiting a great application potential.